Related Experiment Video

Updated: Aug 24, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival

Vivi Ann Flørenes1, Martina Skrede, Kjersti Jørgensen

  • 1Department of Pathology, The Norwegian Radium Hospital, 0310 Oslo, Norway. v.a.florenes@labmed.uio.no

Melanoma Research
|June 5, 2004
PubMed

Insights

The deacetylase inhibitor trichostatin A (TSA) halts melanoma cell cycle progression and triggers apoptosis by upregulating p21(WAF1/CIP1) and reducing p53. This suggests inhibiting deacetylation is a potential melanoma therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Protein acetylation regulates critical cellular processes, including cell cycle control and apoptosis.
  • Malignant melanoma is a significant public health concern, necessitating novel therapeutic strategies.
  • Histone deacetylase inhibitors, such as trichostatin A (TSA), are being investigated for their anti-cancer potential.

Purpose of the Study:

  • To investigate the impact of protein acetylation, modulated by TSA, on cell cycle progression and survival in human malignant melanoma cell lines.
  • To elucidate the specific molecular mechanisms by which TSA affects key cell cycle regulators and apoptosis pathways in melanoma.

Main Methods:

  • Treatment of seven human malignant melanoma cell lines with trichostatin A (TSA).
  • Analysis of cell cycle phase distribution using flow cytometry.
  • Assessment of protein expression levels of key regulators including pRB, p53, p21(WAF1/CIP1), cyclins (D1, D3, A, E), and caspases via Western blotting.
  • Evaluation of apoptosis induction and caspase activity through PARP cleavage and caspase inhibition studies.

Main Results:

  • TSA induced a transient G(2)/M phase delay and accumulation of unphosphorylated retinoblastoma protein (pRB).
  • TSA dose-dependently upregulated p21(WAF1/CIP1) expression and reduced p53 protein levels, independent of ERK1/2 signaling.
  • TSA altered the expression of cyclins, reducing cyclin D1 and A while increasing cyclin D3 and E, and profoundly induced apoptosis via caspase activation.

Conclusions:

  • Protein acetylation, inhibited by TSA, plays a crucial role in regulating cell cycle progression and survival in malignant melanoma.
  • TSA-induced upregulation of p21(WAF1/CIP1) and apoptosis suggests a mechanism for targeting melanoma.
  • Inhibition of deacetylation represents a promising therapeutic strategy for melanoma patients.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...